Javascript must be enabled to continue!
Portal hemodynamics during nitroglycerin administration in cirrhotic patients
View through CrossRef
Nitroglycerin is a potent venous dilator and a mild arterial vasodilator that has been shown to improve the hemodynamic response to vasopressin in portal hypertensive patients and to decrease portal pressure in experimental animals. In order to determine the effect of nitroglycerin on portal venous hemodynamics, we studied 11 patients with alcoholic cirrhosis before and during the administration of sublingual nitroglycerin (0.4 and 0.6 mg). The hepatic venous pressure gradient (which was obtained by subtracting the free hepatic venous pressure from the wedged hepatic venous pressure) decreased from 17.9 ± 6.5 mm Hg (mean ± S.D.) to 15.1 ± 5.1 mm Hg (p < 0.02) at the peak of the effect, which occurred from 2 to 12 min after nitroglycerin administration. The mean arterial pressure was reduced from 96 ± 10 mm Hg to a peak decrease of 76 ± 18 mm Hg (p < 0.001). The peak change in the hepatic venous pressure gradient induced by nitroglycerin correlated directly with the peak change in mean arterial pressure (r = 0.79, p < 0.01). There was a moderate increase in heart rate in response to the decrease in blood pressure (73 ± 15 to 83 ± 15 beats per min, p < 0.001). Two of the 11 patients did not reduce their hepatic venous pressure gradient after 0.6 mg nitroglycerin. Reductions in portal pressure were observed with both increases and moderate decreases in azygos blood flow, suggesting that, as observed in experimental animals, the portal-pressure-reducing effect of nitroglycerin could be due to two different and independent mechanisms, a reduction in portal blood flow or portal-collateral vasodilatation.
Ovid Technologies (Wolters Kluwer Health)
Title: Portal hemodynamics during nitroglycerin administration in cirrhotic patients
Description:
Nitroglycerin is a potent venous dilator and a mild arterial vasodilator that has been shown to improve the hemodynamic response to vasopressin in portal hypertensive patients and to decrease portal pressure in experimental animals.
In order to determine the effect of nitroglycerin on portal venous hemodynamics, we studied 11 patients with alcoholic cirrhosis before and during the administration of sublingual nitroglycerin (0.
4 and 0.
6 mg).
The hepatic venous pressure gradient (which was obtained by subtracting the free hepatic venous pressure from the wedged hepatic venous pressure) decreased from 17.
9 ± 6.
5 mm Hg (mean ± S.
D.
) to 15.
1 ± 5.
1 mm Hg (p < 0.
02) at the peak of the effect, which occurred from 2 to 12 min after nitroglycerin administration.
The mean arterial pressure was reduced from 96 ± 10 mm Hg to a peak decrease of 76 ± 18 mm Hg (p < 0.
001).
The peak change in the hepatic venous pressure gradient induced by nitroglycerin correlated directly with the peak change in mean arterial pressure (r = 0.
79, p < 0.
01).
There was a moderate increase in heart rate in response to the decrease in blood pressure (73 ± 15 to 83 ± 15 beats per min, p < 0.
001).
Two of the 11 patients did not reduce their hepatic venous pressure gradient after 0.
6 mg nitroglycerin.
Reductions in portal pressure were observed with both increases and moderate decreases in azygos blood flow, suggesting that, as observed in experimental animals, the portal-pressure-reducing effect of nitroglycerin could be due to two different and independent mechanisms, a reduction in portal blood flow or portal-collateral vasodilatation.
Related Results
Intermittent Transdermal Nitroglycerin Therapy
Intermittent Transdermal Nitroglycerin Therapy
Background
Intermittent transdermal nitroglycerin therapy is effective in the treatment of stable angina and prevents the development of tolerance. Previous investigati...
Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: An operator-blind echo-Doppler study
Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: An operator-blind echo-Doppler study
In an operator-blind design, we used an echo-Doppler duplex system to examine superior mesenteric artery and portal vein hemodynamics on two consecutive mornings in 12 fasting cirr...
Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
Abstract
Splanchnic vasodilatation contributes to the development and aggravation of portal hypertension (PHT). We previously demonstrated that in cirrhosis, angiotensin‐...
Multiple gastric red spots, capillary ectasia, hypergastrinemia and hypopepsinogenemia i in cirrhosis: A new syndrome?
Multiple gastric red spots, capillary ectasia, hypergastrinemia and hypopepsinogenemia i in cirrhosis: A new syndrome?
To characterize bleeding from gastric red spots in patients with cirrhosis, three groups of patients were studied: (a) 11 cirrhotic patients bleeding from gastric red spots, (b) 18...
Effect of release‐controlled nifedipine on portal hemodynamics in cirrhotic patients
Effect of release‐controlled nifedipine on portal hemodynamics in cirrhotic patients
OBJECTIVE: To evaluate the therapeutic effect of release‐controlled nifedipine on portal hypertension. METHODS: Thirty‐two cirrhotic patients were enrolled to investigate, by using...
Editor's welcome, PORTAL, Vol. 1, No. 1, January 2004
Editor's welcome, PORTAL, Vol. 1, No. 1, January 2004
Welcome to the inaugural issue of PORTAL
On behalf of the Executive Editorial Committee of PORTAL Journal of Multidisciplinary International Studies, it is a great ple...
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis
The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis
AbstractBackground and AimWe evaluated the characteristics of hepatocellular carcinoma (HCC) in patients who had non‐alcoholic fatty liver disease (NAFLD) without cirrhosis.Methods...
Optimizing Cardiovascular Performance Following Myocardial Infarction: The Significance of Nitroglycerin in Regulating Blood Flow
Optimizing Cardiovascular Performance Following Myocardial Infarction: The Significance of Nitroglycerin in Regulating Blood Flow
Background & Objectives: Nitroglycerin, a potent vasodilator, is crucial in managing blood flow dynamics in patients recovering from Myocardial Infarction (MI). This research a...

